SCHEMBL11033990

SCHEMBL11033990

CN1CCN(c2ccc(Nc3cc(Cc4ccccc4Cl)cnc3C(N)=O)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 1/20 0.54
▸ LCK P06239 2/20 0.48
▸ MAPK14 Q16539 1/20 0.48
▸ MAP3K7 O43318 4/20 0.47
▸ STAT6 P42226 2/20 0.47
▸ CDK9 P50750 4/20 0.47
▸ CDK6 Q00534 4/20 0.47
▸ CCNT1 O60563 3/20 0.47
▸ CDK4 P11802 3/20 0.47
▸ CCND1 P24385 3/20 0.47
▸ CDK11A Q9UQ88 3/20 0.47
▸ CSF1R P07333 2/20 0.46
▸ CCNK O75909 1/20 0.46
▸ CCNA2 P20248 1/20 0.46
▸ CDK2 P24941 1/20 0.46
▸ CCND3 P30281 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ ESR2 Q92731 1/20 0.46
▸ EGFR P00533 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11029285 0.91 SLC2A1 (0.49) SLC2A1LCKMAPK14STAT6CDK9
SCHEMBL11030740 0.90 SLC2A1 (0.55) SLC2A1LCKMAPK14MAP3K7STAT6
SCHEMBL11033167 0.89 BTK (0.48) SLC2A1STAT6CDK9CDK6CCNT1
SCHEMBL11025081 0.88 STAT6 (0.55) SLC2A1STAT6CDK9CDK6CCNT1
SCHEMBL11030017 0.88 STAT6 (0.48) SLC2A1STAT6CDK6CDK4CCND1
SCHEMBL11027457 0.88 CDK2 (0.50) SLC2A1LCKMAPK14MAP3K7STAT6
SCHEMBL11029039 0.86 JAK2 (0.52) SLC2A1LCKMAPK14CDK9CDK6
SCHEMBL11025349 0.86 SLC2A1 (0.52) SLC2A1STAT6CDK9CDK6CCNT1
SCHEMBL11029481 0.85 SLC2A1 (0.52) SLC2A1LCKMAPK14MAP3K7STAT6
SCHEMBL11295065 0.84 STAT6 (0.55) SLC2A1STAT6CDK9CDK6CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US claimed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP claimed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN claimed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US claimed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO claimed
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US disclosed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP disclosed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US disclosed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 SLC2A1 3662/4885LCK 17/4885MAPK14 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback